British inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing.
The investment groups Q-Growth Fund and Biolty purchased the majority of the Valencian biotechnology company Institute of Genomic Medicine (Imegen) for €10m.
British Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection.
According to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277m.
Transgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibbs checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer (NSCLC).
Belgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction.
Neurodegeneration specialist Pharnext SA and autoimmune disease expert Galapagos NV have inked an R&D contract in order to expand Pharnexts pleotherapy approach to new indications.
Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Mercks PD-1 inhibitor pembrolizumab in lung cancer patients.
Inhaled lung therapeutics specialist Breath Therapeutics Holding BV closed a Series A financing led by Gimv and Sofinnova.
The UKs Life Sciences sector is more than twice as productive as the UK average, says a new analyst report. However, it doesn’t come close to the productivity in Switzerland or other leading life sciences clusters.